Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions. (2nd September 2017)

• Record Type: Journal Article
• Authors: Adiwidjaja, Jeffry; McLachlan, Andrew J.; Boddy, Alan V.
• Is Part Of: Expert opinion on drug metabolism and toxicology. Volume 13:Number 9(2017:Sep.)
• Page Start: 953
• Page End: 972
• Publication Date: 2017-09-02
• Subjects: Anti-cancer -- bioavailability -- clinical pharmacokinetics -- curcumin -- interaction -- metabolism -- pharmacodynamics; Drugs -- Toxicology -- Periodicals; Drugs -- Metabolism -- Periodicals; 615.7
• DOI: 10.1080/17425255.2017.1360279
• Languages: English
• ISSNs: 1742-5255

Abstract

ABSTRACT: Introduction : Curcumin has been extensively studied for its anti-cancer properties. While a diverse array of in vitro and preclinical research support the prospect of curcumin use as an anti-cancer therapeutic, most human studies have failed to meet the intended clinical expectation. Poor systemic availability of orally-administered curcumin may account for this disparity. Areas covered : This descriptive review aims to concisely summarise available clinical studies investigating curcumin pharmacokinetics when administered in different formulations. A critical analysis of pharmacokinetic- and pharmacodynamic-based interactions of curcumin with concomitantly administered drugs is also provided. Expert opinion : The encouraging clinical results of curcumin administration are currently limited to people with colorectal cancer, given that sufficient curcumin concentrations persist in colonic mucosa. Higher parent curcumin systemic exposure, which can be achieved by several newer formulations, has important implications for optimal treatment of cancers other than those in gastrointestinal tract. Curcumin-drug pharmacokinetic interactions are also almost exclusively in the enterocytes, owing to extensive first pass metabolism and poor curcumin bioavailability. Greater scope of these interactions, i.e. modulation of the systemic elimination of co-administered drugs, may be expected from more-bioavailable curcumin formulations. Further studies are still warranted, especially with newer formulations to support the inclusion of curcumin in cancer therapy regimens.